Anemia at discharge, but not admission, was independently associated with increased all-cause mortality (HR 1.30; 95% CI 1.05-1.60; P=0.015) in hospitalized patients with HFrEF.
Cohort (n=3,731)
Effect estimate: HR 1.30 (95% CI 1.05-1.60)
p-value: p=0.015
BACKGROUND: Anemia has been associated with worse outcomes in patients with chronic heart failure (HF). We aimed to characterize the clinical profile and postdischarge outcomes of hospitalized HF patients with anemia at admission or discharge. METHODS AND RESULTS: An analysis was performed on 3731 (90%) of 4133 hospitalized HF patients with ejection fraction ≤40% enrolled in the Efficacy of Vasopressin Antagonist in Heart Failure Outcome Study with Tolvaptan (EVEREST) trial with baseline hemoglobin data, comparing the clinical characteristics and outcomes (all-cause mortality and cardiovascular mortality or HF hospitalization) of patients with and without anemia (hemoglobin 100 days) on adjusted analysis (both P>0.1). CONCLUSIONS: Among hospitalized HF patients with reduced ejection fraction, modest anemia at discharge but not baseline was associated with increased all-cause mortality and short-term cardiovascular mortality plus HF hospitalization. CLINICAL TRIAL REGISTRATION: URL: http://www.clinicaltrials.gov. Unique identifier: NCT00071331.
Mentz et al. (Wed,) conducted a cohort in Heart failure with reduced ejection fraction (n=3,731). Anemia at discharge vs. No anemia at discharge was evaluated on All-cause mortality (HR 1.30, 95% CI 1.05-1.60, p=0.015). Anemia at discharge, but not admission, was independently associated with increased all-cause mortality (HR 1.30; 95% CI 1.05-1.60; P=0.015) in hospitalized patients with HFrEF.